GMA
Thirty-six adults with fasting glucose between 100 and 125 mg/dL received Metaberine® 200 mg or placebo for 14 days in a randomised double-blind crossover design with a seven-day washout.
Authors report a mean 9.08 mg/dL decrease in fasting glucose, lower glucose area under the curve and peak, and GLP-1 increases of 29% fasting and 22% postprandial. Total cholesterol, LDL and HDL also changed favourably.
The lower-dose formulation is industrially interesting but cannot be generalised without qualification. Short duration, selected population, funding and direct comparison with conventional formulations belong in dossier assessment.
The trial shows why delivery technology should be assessed through dose, finished product and clinical outcomes rather than a bioavailability label alone.
A small 14-day study in healthy adults at metabolic risk and connected to the manufacturer. Longer independent replication is required.
Editorial note. This content is intended for industry professionals. It does not constitute medical advice, therapeutic guidance or regulatory advice. Read our editorial method.
Read the original source · International Journal of Clinical Trials ↗